INTERNATIONAL SURVEY ON WILLINGNESS-TO-PAY (WTP) FOR ONE ADDITIONAL QALY GAINED: WHAT IS THE THRESHOLD OF COST EFFECTIVENESS?

被引:473
|
作者
Shiroiwa, Takeru [1 ]
Sung, Yoon-Kyoung [2 ]
Fukuda, Takashi [3 ]
Lang, Hui-Chu [4 ]
Bae, Sang-Cheol [2 ]
Tsutani, Kiichiro
机构
[1] Univ Tokyo, Dept Drug Policy & Management, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan
[2] Hanyang Univ, Dept Rheumatol, Hosp Rheumat Dis, Seoul 133791, South Korea
[3] Univ Tokyo, Dept Hlth Econ & Epidemiol Res, Sch Publ Hlth, Tokyo 1130033, Japan
[4] Natl Yang Ming Univ, Inst Hosp & Hlth Care Adm, Sch Med, Taipei 112, Taiwan
关键词
cost-effectiveness analysis; threshold; QALY; WTP; double-bound dichotomous choice; ADJUSTED LIFE YEAR;
D O I
10.1002/hec.1481
中图分类号
F [经济];
学科分类号
02 ;
摘要
Although the threshold of cost effectiveness of medical interventions is thought to be 20 pound 000-30 pound 000 in the UK, and $50 000-$100 000 in the US, it is well known that these values are unjustified, due to lack of explicit scientific evidence. We measured willingness-to-pay (WTP) for one additional quality-adjusted life-year gained to determine the threshold of the incremental cost-effectiveness ratio. Our study used the Internet to compare WTP for the additional year of survival in a perfect status of health in Japan, the Republic of Korea (ROK), Taiwan, Australia, the UK, and the US. The research utilized a double-bound dichotomous choice, and analysis by the nonparametric Turnbull method. WTP values were JPY 5 million (Japan), KWN 68 million (ROK). NT$ 2.1 million (Taiwan), 23000 (UK), AU$ 64 000 (Australia), and US$ 62 000 (US). The discount rates of outcome were estimated at 6.8% (Japan), 3.7% (ROK), 1.6% (Taiwan), 2.8% (UK), 1.9% (Australia), and 3.2% (US). Based on the current study, we suggest new classification of cost-effectiveness plane and methodology for decision making. Copyright (C) 2009 John Wiley & Sons, Ltd.
引用
收藏
页码:422 / 437
页数:16
相关论文
共 21 条
  • [1] International survey on WTP for one additional QALY gain - How much is the threshold of cost-effectiveness analysis
    Shiroiwa, T.
    Sung, Y. K.
    Fukuda, T.
    Bae, S. C.
    Tsutani, K.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A179 - A179
  • [2] A PILOT STUDY FOR ESTIMATION OF WILLINGNESS-TO-PAY PER QUALITY ADJUSTED LIFE YEAR (WTP PER QALY) AS COST EFFECTIVENESS THRESHOLD IN INDONESIA
    Endarti, D.
    Andayani, T. M.
    Kristina, S. A.
    Rokhman, M. R.
    [J]. VALUE IN HEALTH, 2018, 21 : S92 - S92
  • [3] EE759 WILLINGNESS-TO-PAY FOR A QALY: A NEW APPROACH TO ESTIMATE COST-EFFECTIVENESS THRESHOLD APPLIED TO FRANCE
    Tehard, B.
    Sambuc, C.
    Midy, F.
    Chevalier, J.
    Roze, S.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S200 - S200
  • [4] How you ask is what you get: Framing effects in willingness-to-pay for a QALY
    Ahlert, Marlies
    Breyer, Friedrich
    Schwettmann, Lars
    [J]. SOCIAL SCIENCE & MEDICINE, 2016, 150 : 40 - 48
  • [5] Estimation of Socio-Economic Cost of Road Accidents in Lithuania: Willingness-To-Pay Approach (WTP)
    Sliupas, T.
    Pakalnis, A.
    [J]. TRANSPORT MEANS 2017, PTS I-III, 2017, : 13 - 18
  • [6] UNDERSTANDING WHAT PATIENTS VALUE AND THEIR WILLINGNESS-TO-PAY (WTP) FOR HEMOPHILIA THERAPIESA DISCRETE CHOICE EXPERIMENT
    Chaugule, S.
    Hay, J. W.
    Young, G.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A230 - A231
  • [7] Establishing cost-effectiveness threshold in China: a community survey of willingness to pay for a healthylife year
    Xu, Lizheng
    Chen, Mingsheng
    Angell, Blake
    Jiang, Yawen
    Howard, Kirsten
    Jan, Stephen
    Si, Lei
    [J]. BMJ GLOBAL HEALTH, 2024, 9 (01):
  • [8] WILLINGNESS-TO-PAY FOR LNS PRODUCTS AND COST-EFFECTIVENESS ESTIMATES FOR THE ILINS PROJECT SITES
    Vosti, S.
    Adams, K.
    Humber, J.
    Phiri, T.
    Ayifah, E.
    Guissou, R.
    Ashorn, P.
    Lartey, A.
    Maneta, K.
    Ouedraogo, J. B.
    Dewey, K.
    [J]. ANNALS OF NUTRITION AND METABOLISM, 2013, 63 : 25 - 25
  • [9] IS THE CHOICE OF WILLINGNESS-TO-PAY THRESHOLD IN COST-UTILITY ANALYSIS ENDOGENOUS TO THE RESULTING VALUE OF THE TECHNOLOGY?
    Padula, W., V
    Chen, H. B.
    Phelps, C. E.
    [J]. VALUE IN HEALTH, 2018, 21 : S362 - S362
  • [10] GENERALIZED PREVALENCE-ADJUSTED WILLINGNESS-TO-PAY TO CONTROL FOR HEALTH EQUITY IN COST-EFFECTIVENESS ANALYSIS
    Pontinha, V
    Padula, W.
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S4 - S4